rss
DTB 42:61-62 doi:10.1136/dtb.2004.42861
  • Articles

▼Moxifloxacin - a new fluoroquinolone antibacterial

  • Relevant BNF section: 5.1.12

Abstract

▼Moxifloxacin (Avelox - Bayer plc), the latest fluoroquinolone antibacterial to be launched in the UK, is licensed for the oral treatment of adults with community-acquired pneumonia, acute exacerbation of chronic bronchitis or acute sinusitis. The company claims that the drug provides "rapid relief from chest infections". Here we review the place of moxifloxacin in treating patients with respiratory tract infections.

Footnotes

    Free sample issue

    This DTB issue is free to all users to allow everyone the opportunity to see the full scope and typical content published in the bulletin.

    View free sample issue >>

    DTB now online first!

    Sign up to receive email alerts when new content is published online before it appears in print.

    Navigate This Article